Pieris Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pieris Pharmaceuticals generated cash of -$53,819,000, which is more than the previous year. Cash used in financing activities reached the amount of $19,795,000 last year. Net change in cash is therefore -$21,239,000.
Cash Flow
| 2014 | -5.06M | -267.40K | 20.33M |
|---|---|---|---|
| 2015 | -12.70M | -620.74K | 24.61M |
| 2016 | -14.38M | -559.67K | 15.22M |
| 2017 | 49.75M | -45.87M | 4.09M |
| 2018 | -1.06M | -8.87M | 48.51M |
| 2019 | -52.46M | 9.83M | 32.16M |
| 2020 | -45.89M | 39.21M | 10.11M |
| 2021 | -7.66M | -949K | 59.12M |
| 2022 | -59.93M | -21.23M | 7.21M |
| 2023 | -53.81M | 12.00M | 19.79M |
PIRS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 38.63M | 117.76M | 70.43M | 62.26M | 74.86M | 37.87M | 29.35M | 29.34M | 18.47M | 3.68M |
Operating activities | ||||||||||
Net income | -24.54M | -33.27M | -45.73M | -37.23M | -25.46M | -26.75M | -17.64M | -22.79M | -14.05M | -9.84M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.78M | 2.78M | 2.36M | 2.12M | 1.04M | 570K | 369K | 361.38K | 307.90K | 366.97K |
Stock-based compensation expense | 3.34M | 4.40M | 5.21M | 5.09M | 5.37M | 0 | 3.04M | 1.90M | 1.16M | 571.38K |
| Deferred income tax benefit | 3.34M | 4.40M | 5.21M | 5.09M | 5.37M | 0 | 3.04M | 1.90M | 1.16M | 571.38K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 5.30M | -2.62M | -1.81M | 5.34M | -4.05M | 12.51M | -14.46M | -58.65K | 0 | 465.38K |
Inventories | 0 | 0 | 5.73M | -2.87M | -799K | 0 | 3.96M | 1.04M | 0 | -1.05M |
Accounts payable | -789K | -4.20M | 7.04M | -4.35M | 1.25M | 764K | -332K | 1.36M | -90.92K | 1.11M |
Cash generated by operating activities | -53.81M | -59.93M | -7.66M | -45.89M | -52.46M | -1.06M | 49.75M | -14.38M | -12.70M | -5.06M |
Investing activities | ||||||||||
Purchases Of Investments | -22.83M | -48.39M | 0 | -41.49M | -59.31M | -117.58M | -43.92M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -171K | -1.04M | -949K | -2.72M | -2.46M | -1.69M | -1.95M | -580.63K | -620.74K | -267.40K |
Acquisitions Net | -12.17M | 20.19M | 0 | -41.93M | -12.3M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 12.00M | -21.23M | -949K | 39.21M | 9.83M | -8.87M | -45.87M | -559.67K | -620.74K | -267.40K |
Financing activities | ||||||||||
Common Stock Issued | 19.79M | 6.92M | 57.10M | 9.62M | 30.99M | 47.21M | 4.09M | 15.22M | 25.76M | 11.96M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.15M | -181.51K |
Cash used in financing activities | 19.79M | 7.21M | 59.12M | 10.11M | 32.16M | 48.51M | 4.09M | 15.22M | 24.61M | 20.33M |
Net Change In Cash | -21.23M | -79.12M | 47.32M | 8.17M | -12.60M | 36.98M | 8.52M | 6.40K | 10.87M | 14.78M |
Cash at end of period | 17.39M | 38.63M | 117.76M | 70.43M | 62.26M | 74.86M | 37.87M | 29.35M | 29.34M | 18.47M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |